Recent research reveals that inhibiting the tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) pathway makes cells more susceptible to cell death, suggesting that BRMS1+ BC patients may benefit from TRAIL-targeted therapy [71]. Here, TNFSF10 is linked to breast cancer.